title: Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
abstract: BACKGROUND
  Lysosome-associated protein transmembrane 4b-35 (LAPTM4B-35) is a member of the mammalian 4-tetratransmembrane spanning protein superfamily, which is overexpressed in several solid malignancies. However, the expression of LAPTM4B-35 and its role in the progression of prostate cancer (PCa) is unknown. The aim of the present study was to investigate the LAPTM4B-35 expression in PCa and its potential relevance to clinicopathological variables and prognosis.
  
  
  METHODS
  Immunohistochemistry was used to determine the expression of LAPTM4B-35 protein in 180 PCa tissues in comparison with 180 normal benign prostatic hyperplasia (BPH) specimens. The correlation between the expression of the LAPTM4B-35 protein and the clinicopathologic characteristics of patients with PCa was analyzed.
  
  
  RESULTS
  Statistical analysis showed that LAPTM4B-35 expression was significantly elevated in PCa compared with the BPH controls. High LAPTM4B-35 staining was present in 71.11% of all the cases with PCa. The overexpression of LAPTM4B-35 was significantly associated with the lymph node metastasis, seminal vesicle invasion, PCa stage, higher Gleason score, higher preoperative PSA, and biochemical recurrence (BCR). The Kaplan-Meier survival analysis showed that the high expression of LAPTM4B-35 was related to the poor overall survival and BCR-free survival of patients with PCa. Multivariate Cox analysis showed that LAPTM4B-35 was an independent prognostic factor for both overall survival and BCR-free survival of patients with PCa.
  
  
  CONCLUSIONS
  Overexpression of LAPTM4B-35 may be associated with tumor progression and poor prognosis in PCa and thus may serve as a new molecular marker to predict the prognosis of PCa patients.
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Hongtuan
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wei
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Ranlu
authors.initials: R
authors.lastname: Liu
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Shiyong
authors.initials: S
authors.lastname: Qi
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Peihe
authors.initials: P
authors.lastname: Liang
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Can
authors.initials: C
authors.lastname: Qi
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Andi
authors.initials: A
authors.lastname: Wang
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Sheng
authors.affiliation: Department of Radiology, Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Urology, National Key Clinical Specialty of Urology, Second Hospital of Tianjin Medical University, Tianjin Key Institute of Urology, Tianjin Medical University, Tianjin, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Xu
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D015513:Oncogene Proteins / Q000378:metabolism*; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; C477083:LAPTM4B protein, human; D008565:Membrane Proteins; D015513:Oncogene Proteins